Literature DB >> 22503074

Lung disease with anti-CCP antibodies but not rheumatoid arthritis or connective tissue disease.

Aryeh Fischer1, Joshua J Solomon, Roland M du Bois, Kevin D Deane, Amy L Olson, Evans R Fernandez-Perez, Tristan J Huie, Allen D Stevens, Mary B Gill, Avi M Rabinovitch, David A Lynch, David A Burns, Isabel S Pineiro, Steve D Groshong, Rosane D Duarte Achcar, Kevin K Brown, Richard J Martin, Jeffrey J Swigris.   

Abstract

OBJECTIVE: We sought to characterize a novel cohort of patients with lung disease, anti-cyclic citrullinated peptide (CCP) antibody positivity, without rheumatoid arthritis (RA) or other connective tissue disease (CTD).
METHODS: The study sample included 74 subjects with respiratory symptoms, evaluated January 2008-January 2010 and found to have a positive anti-CCP antibody but no evidence for RA or other CTD. Each underwent serologic testing, pulmonary physiology testing, and thoracic high-resolution computed tomography (HRCT) scan as part of routine clinical evaluation.
RESULTS: The majority of subjects were women, and most were former cigarette smokers. Four distinct radiographic phenotypes were identified: isolated airways disease (54%), isolated interstitial lung disease (ILD) (14%), mixed airways disease and ILD (26%), and combined pulmonary fibrosis with emphysema (7%). This cohort had a predominance of airways disease, either in isolation or along with a usual interstitial pneumonia-pattern of ILD. Among subjects with high-titer anti-CCP positivity (n=33), three developed the articular manifestations of RA during a median follow-up of 449 days.
CONCLUSION: We have described a unique cohort of patients with anti-CCP antibody positivity and lung disease in the absence of existing RA or other CTD. The lung phenotypic characteristics of this cohort resemble those of established RA and a few of these patients have developed articular RA within a short period of follow-up. The implications of a positive anti-CCP antibody among patients with lung disease but not RA are not yet known, but we believe requires further investigation.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503074      PMCID: PMC3753791          DOI: 10.1016/j.rmed.2012.03.006

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  21 in total

1.  The syndrome of combined pulmonary fibrosis and emphysema.

Authors:  Vincent Cottin; Jean-François Cordier
Journal:  Chest       Date:  2009-07       Impact factor: 9.410

2.  A clue to diagnosing connective tissue disease-associated interstitial lung disease.

Authors:  Shinji Teramoto; Kosaku Komiya; Shunsuke Akashi; Masahiro Kawashima
Journal:  Chest       Date:  2011-03       Impact factor: 9.410

3.  Connective tissue disease-associated interstitial lung disease: a call for clarification.

Authors:  Aryeh Fischer; Sterling G West; Jeffrey J Swigris; Kevin K Brown; Roland M du Bois
Journal:  Chest       Date:  2010-08       Impact factor: 9.410

Review 4.  Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation.

Authors:  Kevin D Deane; Jill M Norris; V Michael Holers
Journal:  Rheum Dis Clin North Am       Date:  2010-05       Impact factor: 2.670

Review 5.  Pulmonary pathology of the rheumatic diseases.

Authors:  Kevin O Leslie; Sylvain Trahan; James Gruden
Journal:  Semin Respir Crit Care Med       Date:  2007-08       Impact factor: 3.119

6.  Comparison of second- and third-generation anti-cyclic citrullinated peptide antibodies assays for detecting rheumatoid arthritis.

Authors:  Laurence Lutteri; Michel Malaise; Jean-Paul Chapelle
Journal:  Clin Chim Acta       Date:  2007-08-16       Impact factor: 3.786

7.  Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells.

Authors:  D Makrygiannakis; M Hermansson; A-K Ulfgren; A P Nicholas; A J W Zendman; A Eklund; J Grunewald; C M Skold; L Klareskog; A I Catrina
Journal:  Ann Rheum Dis       Date:  2008-04-15       Impact factor: 19.103

8.  Anti-cyclic citrullinated peptide antibodies in lung diseases associated with rheumatoid arthritis.

Authors:  Naoki Inui; Noriyuki Enomoto; Takafumi Suda; Yasunori Kageyama; Hiroshi Watanabe; Kingo Chida
Journal:  Clin Biochem       Date:  2008-07-03       Impact factor: 3.281

9.  Rheumatoid arthritis (RA)-specific autoantibodies in patients with interstitial lung disease and absence of clinically apparent articular RA.

Authors:  Alison M Gizinski; Margherita Mascolo; Jennifer L Loucks; Alma Kervitsky; Richard T Meehan; Kevin K Brown; V Michael Holers; Kevin D Deane
Journal:  Clin Rheumatol       Date:  2009-02-28       Impact factor: 2.980

10.  The anti-cyclic citrullinated peptide response in tuberculosis patients is not citrulline-dependent and sensitive to treatment.

Authors:  Ori Elkayam; Refael Segal; Daniele Bendayan; Robert van Uitert; Carla Onnekink; Ger Jm Pruijn
Journal:  Arthritis Res Ther       Date:  2010-01-25       Impact factor: 5.156

View more
  62 in total

1.  Interstitial lung disease associated with anti-citrullinated peptide/protein antibody-positive anti-synthetase syndrome.

Authors:  Hideaki Yamakawa; Eri Hagiwara; Tae Iwasawa; Ryota Otoshi; Erina Tabata; Satoshi Ikeda; Ryo Okuda; Tomohisa Baba; Shinichiro Iso; Koji Okudela; Tamiko Takemura; Shinji Sato; Takashi Ogura
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Form, Function, and Dysfunction: Airway Diseases Are Associated With Increased Risk for Rheumatoid Arthritis.

Authors:  Maor Sauler
Journal:  Arthritis Rheumatol       Date:  2020-04-08       Impact factor: 10.995

Review 3.  Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.

Authors:  Anca I Catrina; Kevin D Deane; Jose U Scher
Journal:  Rheumatology (Oxford)       Date:  2014-12-23       Impact factor: 7.580

4.  Anti-Citrullinated Protein Antibodies Are Associated With Neutrophil Extracellular Traps in the Sputum in Relatives of Rheumatoid Arthritis Patients.

Authors:  M Kristen Demoruelle; Kylie K Harrall; Linh Ho; Monica M Purmalek; Nickie L Seto; Heather M Rothfuss; Michael H Weisman; Joshua J Solomon; Aryeh Fischer; Yuko Okamoto; Lindsay B Kelmenson; Mark C Parish; Marie Feser; Chelsie Fleischer; Courtney Anderson; Michael Mahler; Jill M Norris; Mariana J Kaplan; Brian D Cherrington; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheumatol       Date:  2017-05-02       Impact factor: 10.995

5.  Timing of Elevations of Autoantibody Isotypes Prior to Diagnosis of Rheumatoid Arthritis.

Authors:  Lindsay B Kelmenson; Brandie D Wagner; Bryan K McNair; Ashley Frazer-Abel; M Kristen Demoruelle; Dylan T Bergstedt; Marie L Feser; Laura K Moss; Mark C Parish; Elizabeth A Mewshaw; Ted R Mikuls; Jess D Edison; V Michael Holers; Kevin D Deane
Journal:  Arthritis Rheumatol       Date:  2019-12-26       Impact factor: 10.995

6.  Safe exposure level for diacetyl.

Authors:  Kendal B Wallace; Gilman D Veith
Journal:  Int J Occup Environ Health       Date:  2014 Jan-Mar

Review 7.  Individuals at risk of seropositive rheumatoid arthritis: the evolving story.

Authors:  S Rantapää Dahlqvist; F Andrade
Journal:  J Intern Med       Date:  2019-10-21       Impact factor: 8.989

Review 8.  Obstructive lung diseases and risk of rheumatoid arthritis.

Authors:  H Maura Friedlander; Julia A Ford; Alessandra Zaccardelli; Alexsandra V Terrio; Michael H Cho; Jeffrey A Sparks
Journal:  Expert Rev Clin Immunol       Date:  2020-01-06       Impact factor: 4.473

Review 9.  The Roles of Cigarette Smoking and the Lung in the Transitions Between Phases of Preclinical Rheumatoid Arthritis.

Authors:  Jeffrey A Sparks; Elizabeth W Karlson
Journal:  Curr Rheumatol Rep       Date:  2016-03       Impact factor: 4.592

10.  Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.

Authors:  José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante
Journal:  Clin Rheumatol       Date:  2015-08-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.